YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE. ==ANENCEPHALY== 1 AUTHOR Oakley GP Jr AUTHOR Adams MJ AUTHOR Dickinson CM TITLE More folic acid for everyone, now. SOURCE J Nutr 1996 Mar;126(3):751S-755S ABSTRACT Research during the last 5 years has made it clear that people who do not take folic acid supplements are at increased risk for functional folate deficiency, which has been proven to cause spina bifida and anencephaly and also has been associated with an increased risk for occlusive cardiovascular disease. The overriding folate policy issue is how to increase dramatically the folate consumption of 75% of the population who are now consuming 0.4 mg of folic acid in a supplement. The most expeditious way to increase consumption is through fortification of a food staple. Public health programs are also needed to educate people about the vital importance of increased consumption of folic acid vitamin supplements and of food rich in natural folates. It is urgent that fortification of cereal-grain products be implemented now. The level proposes by FDA would accomplish some prevention, but much more prevention would occur if the fortification were 2.5 times that level. Fortification at the higher level would prevent about 1000 spina bifida and anencephaly birth defects each year and perhaps as many as 50,000 premature deaths each year from coronary disease. Available data have not demonstrated that increasing consumption of folic acid by 0.1 to 0.25 mg of folic acid a day is harmful. If a policy needs to be established on the assumption that people who take vitamin supplements could be harmed, a good policy option ia available; require that all folic acid vitamin supplements also contain 0.4 mg of vitamin B-12. 4 AUTHOR Oakley GP Jr AUTHOR Erickson JD AUTHOR James LM AUTHOR Mulinare J AUTHOR Cordero JF TITLE Prevention of folic acid-preventable spina bifida and anencephaly. SOURCE Ciba Found Symp; VOL 181, 1994, P212-23; discussion 223-31 (REF: 20) ABSTRACT The results of the British Medical Research Council's randomized controlled trial proved that folic acid can prevent spina bifida and anencephaly. The trial provided critical scientific data upon which to base public health policy for preventing folic acid-preventable spina bifida and anencephaly. Within weeks of publication of the results, the Centers for Disease Control and Prevention in the US developed and issued guidelines for women who had had a pregnancy affected by spina bifida or anencephaly. A year later, the US Public Health Service issued the recommendation that all women of child-bearing age who are capable of becoming pregnant should consume 0.4 mg of folic acid per day. The Public Health Service needed a year to make inferential judgements about dose, target groups, safety, timing of ingestion, and existing and proposed vitamin and drug policies and regulations. Current policy discussions concern whether to permit manufacturers of vitamins or food products to claim that folic acid will prevent folic acid-preventable spina bifida and anencephaly and whether to allow a food staple to be fortified with folic acid. 10 AUTHOR Lemire RJ AUTHOR Siebert JR TITLE Anencephaly: its spectrum and relationship to neural tube defects. SOURCE J Craniofac Genet Dev Biol 1990;10(2):163-74 ABSTRACT Anencephaly patients are of renewed interest because they are regarded as a potential source of organ donation. While there has been a longstanding scientific curiosity on this subject, studies have frequently included such cases as part of the larger spectrum of neural tube defects (NTDs). This paper will discuss some unusual features of anencephaly. Following a review of classification and pathogenesis, associated malformations, growth parameters (organ size and anthropometric measurements), and associations with other entities are discussed. Finally, the relationship of anencephaly to NTDs is presented. 14 AUTHOR Borman GB AUTHOR Smith AH AUTHOR Howard JK TITLE Risk factors in the prevalence of anencephalus and spina bifida in New Zealand. SOURCE Teratology; VOL 33, ISS 2, 1986, P221-30 (REF: 74) ABSTRACT This paper presents results from an epidemiological study on the 51 anencephalus and 53 spina bifida cases in the 1978 New Zealand birth cohort. Multiple sources were used in the ascertainment, and the prevalence rates were 0.98 and 1.02 per 1,000 total births, respectively. No association was found with the traditional indicators of the effect of environmental factors: maternal age, social class, nuptiality, month of birth, or estimated month of conception. Males comprised 41% of anencephalus and 36% of spina bifida cases; the prevalence was higher in the non-Maori than in the Maori population. New Zealand-born mothers appear to have a much lower risk of spina bifida, but not anencephaly, than those born in England/Scotland. The rate for the latter population was within the range of a number of UK-based studies. As the bloodstock of New Zealand whites has been predominantly derived from the UK population, and as New Zealand is a low prevalence area, this suggests that the higher risk for these women is likely to be attributable to factors present in their birthplace but absent in New Zealand. These findings provide further evidence that the epidemiologic patterns of anencephalus and spina bifida in low-prevalence areas are at variance with those in high-prevalence areas, such as the United Kingdom. They also support the hypothesis that the contrast in rates between high- and low-prevalence areas is a reflection of the impact of environmental factors in high-prevalence areas on the "background" or baseline frequency of anencephalus and spina bifida found in low-prevalence areas.